Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines and Quadrivalent Vaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by Age Group (Pediatrics and Adults) and by Region - Global Forecast to 2026

Influenza Vaccines Market Insights – To Stop the Flu Is All Up to You

Influenza is a contagious respiratory infection caused due to influenza virus. Influenza is marked by fever, cough, muscles and joint pain, headache, and severe weakness. Illness due to influenza ranges from mild to severe, occasionally leading to death. According to World Health Organization (WHO), 2018, influenza cases related hospitalization ranges in 3-5 million cases for severe illness, whereas deaths related to influenza are about 290 000 to 650 000. Vaccines are recommended for the prevention of influenza infections. Influenza vaccine can be inactivated influenza vaccine, adjuvant inactivated influenza vaccine, live attenuated influenza vaccine or recombinant influenza vaccine. The rapid spread of influenza virus epidemics worldwide is propelling demands for development of efficient influenza vaccine. Strong product pipeline is the key factor driving growth of the market during the forecast period.

The global influenza vaccines market was valued to be US$ 3,991.4 million in 2017 and is expected to witness a CAGR of 4.4% over the forecast period (2018 – 2026).

Figure 1. Global Influenza Vaccines Market Share (%), By Vaccine Type

influenza vaccines market

Source: Coherent Market Insights Analysis (2018)

Increasing Product Approval for Influenza Vaccine is Propelling Growth of the Influenza Vaccines Market

Increasing seasonal outbreak of influenza virus is propelling demand for better vaccines. Increasing number of approved product is expected to augment growth of the influenza vaccines market. For instance, Seqirus Vaccine Limited, received FDA approval for Afluria Quadrivalent in August 2016, Afluria Trivalent, Flucelvax Quadrivalent in May 2016, and Fluad in November, 2015. Moreover, increasing strong pipeline candidates for influenza vaccine is also expected to boost the market growth. Furthermore, in May 2018, FluGen, Inc., a clinical stage vaccine developing company, started clinical trial for investigation of influenza vaccine, M2SR.

Increasing governmental initiatives to led new path for vaccine development is also expected to propel the market growth. For instance, in April 2018, the Bill and Malinda Gates Foundation and Lucy and Larry Page announced US$ 12 million for researchers to come up with innovative ideas for safe, effective and affordable flu vaccines. Moreover, in May 2018, National Institute of Allergy and Infectious Disease (NIAID), sponsored trial of universal influenza vaccine. Furthermore, governmental initiative for increasing the vaccine supply is propelling growth of the influenza vaccine market.

The constant mutation in genetic structure of influenza virus results in emergence of new virus, unaffected by currently available influenza vaccines. These continuously evolving virus is expected to be the major restrain for growth of the influenza vaccine market. Moreover, high cost of vaccine development is also expected to hinder market growth over the forecast period.

Asia Pacific market to exhibit fastest growth over the forecast period

Regionally, Alzheimer therapeutic market is segmented into six regions - North America, Latin America, Europe, Asia Pacific, Middle East, and Africa by Coherent Market Insights. North America holds dominant position in seasonal influenza vaccine market attributing to increasing R&D activities by market player in cooperation with government support to add novel product to their product portfolio and increasing burden of influenza infection. For instance, US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Conducted under an FDA Investigational New Drug (IND), are sponsoring clinical trials of universal influenza vaccine. However, Asia Pacific is expected to witness fastest growth during forecast period.

Inorganic strategies by the key players is fuelling growth of the influenza vaccine market

The key players involved in influenza vaccines market include Seqirus Vaccines Limited, GlaxoSmithKline plc, Sanofi, and MedImmmune LLC. Furthermore, companies having products in pipeline includes FluGen, Moderna Therapeutics, Novavax, and BioCryst.

Strategic merger and collaboration by the market players is boosting growth of the
influenza vaccine market. For instance, in 2015, BioCryst Pharmaceuticals, entered into license agreement with Seqirus Vaccine Limited, under which Seqirus grants worldwide rights to BioCrysts flu Treatment. Moreover, in August 2017, Sanofi acquired Protein Science Corporation. The acquisition added Flubok, the only FDA approved recombinant protein based influenza vaccine to the Sanofi’s product portfolio.

Influenza, also called as flu or grippe is an acute viral infection of respiratory tract. The disease can be remarked by symptoms such as fevers, chills, and weakness coupled with soreness in head and abdomen.  Influenza flu has prevention as well as treatments. Prevention includes vaccines for protection against influenza virus for upcoming seasons. Based on effectiveness of the vaccine against number of flu virus, the vaccines are classified as trivalent vaccine (three flu virus) or quadrivalent (four flu virus). Vaccine can be administered intramuscular, intranasal or intradermal.  Increasing pipelines products, rising disease prevalence, and new entrant aiming to manufacture influenza vaccine by novel technology such as cell-based or recombinant based are the key factors driving growth of the influenza vaccine market.

Market Dynamics

The significant growth of influenza vaccine market is expected to be attributed by rich pipeline product with novel approach by the major market players as well as the emerging market players. For instance, Mymetrics Corporation is evaluating influenza vaccine via intra nasal form of dosage to inhibit the virus at mucosal level by developing mucosal as well as blood antibodies. Moreover, companies are planning strategically to reduce the burden of vaccine development via partnering with other manufacturers. For instance, the influenza vaccine of Mymetics is been developed with Abbott Biologicals under the contract of out-licensing. Moreover, the governmental organization are continuously aiming to propel the study of universal influenza vaccine to reduce the epidemiology to influenza virus during the seasonal outbreaks. For instance, in 2018, the Human Vaccines Project, a nonprofit consortium of academic, government and industry medical researchers, is engaged in launching Universal Influenza Vaccine Initiative to accelerate the development of universal influenza vaccine.

Key features of the study:

  • This report provides in-depth analysis of the influenza vaccine market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global influenza vaccine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Seqirus Vaccines Limited, GlaxoSmithKline plc, ID Biomedical Corporation, Sanofi, Protein Sciences Corp., and MedImmmune LLC
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics.
  • The global influenza vaccine market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of influenza vaccine, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the influenza vaccine market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Influenza Vaccine Market, By Vaccine Type:
    • Trivalent Vaccines
    • Quadrivalent Vaccines
  • Global Influenza Vaccine Market, By Virus Type:
    • Influenza Virus A
    • Influenza Virus B
  • Global Influenza Vaccine Market, By Age Group:
    • Pediatrics
    • Adults
  • Global Influenza Vaccine Market, By Region:
    • North America
      • By Vaccine Type:
        • Trivalent Vaccines
        • Quadrivalent Vaccines
      • By Virus Type:
        • Influenza Virus A
        • Influenza Virus B
      • By Age Group:
        • Pediatrics
        • Adults
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Vaccine Type:
        • Trivalent Vaccines
        • Quadrivalent Vaccines
      • By Virus Type:
        • Influenza Virus A
        • Influenza Virus B
      • By Age Group:
        • Pediatrics
        • Adults
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Vaccine Type:
        • Trivalent Vaccines
        • Quadrivalent Vaccines
      • By Virus Type:
        • Influenza Virus A
        • Influenza Virus B
      • By Age Group:
        • Pediatrics
        • Adults
      • By Country:
        • Germany
        • U.K.
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Vaccine Type:
        • Trivalent Vaccines
        • Quadrivalent Vaccines
      • By Virus Type:
        • Influenza Virus A
        • Influenza Virus B
      • By Age Group:
        • Pediatrics
        • Adults
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Vaccine Type:
        • Trivalent Vaccines
        • Quadrivalent Vaccines
      • By Virus Type:
        • Influenza Virus A
        • Influenza Virus B
      • By Age Group:
        • Pediatrics
        • Adults
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Vaccine Type:
        • Trivalent Vaccines
        • Quadrivalent Vaccines
      • By Virus Type:
        • Influenza Virus A
        • Influenza Virus B
      • By Age Group:
        • Pediatrics
        • Adults
      • By Country:
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
      • Seqirus Vaccines Limited*
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • GlaxoSmithKline plc
      • Sanofi
      • MedImmmune LLC

Strategies “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
    • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Vaccine Type
      • Market Snippet, By Virus Type
      • Market Snippet, By Age Group
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Industry Trends
    • Pipeline Products
    • Regulatory Scenario
    • Epidemiology
    • PEST Analysis
    • PORTER’S Five Forces
  4. Global Influenza Vaccine Market, By Vaccine Type, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Trivalent Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
    • Quadrivalent Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
  5. Global Influenza Vaccine Market, By Virus Type, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Influenza Virus Type A
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
    • Influenza Virus Type B
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
  6. Global Influenza Vaccine Market, By Age Group, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Pediatrics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
    • Adults
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2026, (US$ Million)
  7. Global Influenza Vaccine Market, By Region, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2017 - 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Virus Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • Northern Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Seqirus Vaccines Limited*
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • ID Biomedical Corporation
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Protein Sciences Corp.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • MedImmune LLC
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 32 market data tables and 30 figures on “Influenza Vaccine Market - Global forecast to 2026”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.